Loading...
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.
Mullen, Lisa Rigby, Anne Sclanders, Michelle Adams, Gill Mittal, Gayatri Colston, Julia Fatah, Rewas Subang, Cristina Foster, Julie Francis-West, Philippa
Mullen, Lisa
Rigby, Anne
Sclanders, Michelle
Adams, Gill
Mittal, Gayatri
Colston, Julia
Fatah, Rewas
Subang, Cristina
Foster, Julie
Francis-West, Philippa
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2014-01
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 376.9 KB
Loading...
figure 1
TIFF, 354.84 KB
Loading...
figues 2 A to D
TIFF, 1.31 MB
Loading...
figures 2 E to H
TIFF, 2.5 MB
Loading...
figure 3
TIFF, 324.51 KB
Other Titles
Abstract
Targeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes.
Citation
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. 2014, 11 (1):5-16 Expert Opin Drug Deliv
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1744-7593
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to Expert opinion on drug delivery